Literature DB >> 30776373

Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons.

Blaine A Jacobs1, Miryam M Pando1, Elaine M Jennings1, Raehannah J Jamshidi1, Joshua C Zamora1, Teresa S Chavera1, William P Clarke1, Kelly A Berg2.   

Abstract

Receptor heteromers often display distinct pharmacological and functional properties compared to the individual receptor constituents. In this study, we compared the properties of the DOP-KOP heteromer agonist, 6'-guanidinonaltrindole (6'-GNTI), with agonists for DOP ([D-Pen2,5]-enkephalin [DPDPE]) and KOP (U50488) in peripheral sensory neurons in culture and in vivo. In primary cultures, all three agonists inhibited PGE2-stimulated cAMP accumulation as well as activated extracellular signal-regulated kinase 1/2 (ERK) with similar efficacy. ERK activation by U50488 was Gi-protein mediated but that by DPDPE or 6'-GNTI was Gi-protein independent (i.e., pertussis toxin insensitive). Brief pretreatment with DPDPE or U50488 resulted in loss of cAMP signaling, however, no desensitization occurred with 6'-GNTI pretreatment. In vivo, following intraplantar injection, all three agonists reduced thermal nociception. The dose-response curves for DPDPE and 6'-GNTI were monotonic whereas the curve for U50488 was an inverted U-shape. Inhibition of ERK blocked the downward phase and shifted the curve for U50488 to the right. Following intraplantar injection of carrageenan, antinociceptive responses to either DPDPE or U50488 were transient but could be prolonged with inhibitors of 12/15-lipoxgenases (LOX). By contrast, responsiveness to 6'-GNTI remained for a prolonged time in the absence of LOX inhibitors. Further, pretreatment with the 12/15-LOX metabolites, 12- and 15- hydroxyeicosatetraenoic acid, abolished responses to U50488 and DPDPE but had no effect on 6'-GNTI-mediated responses either in cultures or in vivo. Overall, these results suggest that DOP-KOP heteromers exhibit unique signaling and functional regulation in peripheral sensory neurons and may be a promising therapeutic target for the treatment of pain.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30776373      PMCID: PMC6500751          DOI: 10.1016/j.neuropharm.2019.02.019

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  59 in total

1.  6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.

Authors:  Marie-Laure Rives; Mary Rossillo; Lee-Yuan Liu-Chen; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

Review 2.  Opioid Receptors.

Authors:  Christoph Stein
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

Review 3.  Methods to monitor the quaternary structure of G protein-coupled receptors.

Authors:  Graeme Milligan; Michel Bouvier
Journal:  FEBS J       Date:  2005-06       Impact factor: 5.542

Review 4.  Functional selectivity and classical concepts of quantitative pharmacology.

Authors:  Jonathan D Urban; William P Clarke; Mark von Zastrow; David E Nichols; Brian Kobilka; Harel Weinstein; Jonathan A Javitch; Bryan L Roth; Arthur Christopoulos; Patrick M Sexton; Keith J Miller; Michael Spedding; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2006-06-27       Impact factor: 4.030

5.  Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity.

Authors:  Ivone Gomes; Wakako Fujita; Achla Gupta; S Adrian Saldanha; Adrian S Saldanha; Ana Negri; Christine E Pinello; Christina Eberhart; Edward Roberts; Marta Filizola; Peter Hodder; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

6.  Functional selectivity of kappa opioid receptor agonists in peripheral sensory neurons.

Authors:  Raehannah J Jamshidi; Blaine A Jacobs; Laura C Sullivan; Teresa A Chavera; Rachel M Saylor; Thomas E Prisinzano; William P Clarke; Kelly A Berg
Journal:  J Pharmacol Exp Ther       Date:  2015-08-21       Impact factor: 4.030

7.  International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands.

Authors:  Arthur Christopoulos; Jean-Pierre Changeux; William A Catterall; Doriano Fabbro; Thomas P Burris; John A Cidlowski; Richard W Olsen; John A Peters; Richard R Neubig; Jean-Philippe Pin; Patrick M Sexton; Terry P Kenakin; Frederick J Ehlert; Michael Spedding; Christopher J Langmead
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

Review 8.  G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.

Authors:  Sergi Ferré; Vicent Casadó; Lakshmi A Devi; Marta Filizola; Ralf Jockers; Martin J Lohse; Graeme Milligan; Jean-Philippe Pin; Xavier Guitart
Journal:  Pharmacol Rev       Date:  2014-02-10       Impact factor: 25.468

9.  Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain.

Authors:  Ilona Obara; Jan Rodriguez Parkitna; Michal Korostynski; Wioletta Makuch; Dorota Kaminska; Barbara Przewlocka; Ryszard Przewlocki
Journal:  Pain       Date:  2009-01-14       Impact factor: 6.961

10.  Peripheral delta opioid receptors require priming for functional competence in vivo.

Authors:  Matthew P Rowan; Nikita B Ruparel; Amol M Patwardhan; Kelly A Berg; William P Clarke; Kenneth M Hargreaves
Journal:  Eur J Pharmacol       Date:  2008-11-25       Impact factor: 4.432

View more
  5 in total

1.  The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.

Authors:  Diana Vivian Atigari; Kelly Frances Paton; Rajendra Uprety; András Váradi; Amy Frances Alder; Brittany Scouller; John H Miller; Susruta Majumdar; Bronwyn Maree Kivell
Journal:  Neuropharmacology       Date:  2020-12-28       Impact factor: 5.250

Review 2.  Strategies towards safer opioid analgesics-A review of old and upcoming targets.

Authors:  Balazs R Varga; John M Streicher; Susruta Majumdar
Journal:  Br J Pharmacol       Date:  2021-11-26       Impact factor: 9.473

Review 3.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

4.  Confronting the opioid crisis with basic research in neuropharmacology.

Authors:  Michael H Baumann; Gavril W Pasternak; Sidney S Negus
Journal:  Neuropharmacology       Date:  2020-01-17       Impact factor: 5.250

Review 5.  GPCR heteromers: An overview of their classification, function and physiological relevance.

Authors:  Natasha C Dale; Elizabeth K M Johnstone; Kevin D G Pfleger
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-30       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.